Urologix seeks US OK for ThermoCath BPH (benign prostatic hyperplasia) therapy:
This article was originally published in Clinica
Executive Summary
Urologix has filed an application with the US FDA for approval to market its minimally invasive Cooled ThermoCath system for treating benign prostatic hyperplasia (BPH). The device uses targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort, says the Minneapolis, Minnesota firm. Urologix adds that pending US approval, it anticipates launching the product in the autumn this year.